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Identity 
Other names: E2F-4 




E2F4 gene spans 6753 base pairs. 
Transcription 
E2F4 gene produces 1 transcript of 2100 bp that counts 
10 exons. 
 
Table adapted from Ensembl. 
Pseudogene 
E2F4P1 (E2F Transcription Factor 4, p107/p130-
binding pseudogene 1).  
Location: 6p21.2 (39521587-39522719). 
Protein 
Description 
The E2F4 coding sequence yields a 413-amino acid 
protein predicting a molecular weight of 44 kDa. 
However, E2F4 migrates as an heterogeneous set of 
bands between 57-64 kDa which are associated with 
extensive phosphorylations (Beijersbergen et al., 1994; 
Ginsberg et al., 1994; Vairo et al., 1995; Gaubatz et al., 
2001; Popov et al., 2005; Araki et al., 2008; Scime et 
al., 2008; Van Hoof et al., 2009; Litovchick et al., 
2011). 
Unlike E2F1, E2F2 and E2F3, which exhibit a cyclin A 
binding domain at their N-terminus, E2F4 has a 
truncated N-terminus and therefore does not harbor this 
domain (Beijersbergen et al., 1994; Sardet et al., 1995).  
The full E2F transcriptional activity requires its 
heterodimerization with a DP partner, although E2F 
transcription factors have been reported to bind DNA 
as homodimers (Bandara et al., 1993; Helin et al., 
1993b; Huber et al., 1993; Krek et al., 1993). The 
DNA-binding domain of E2F4 was originally viewed 
as a helix-loop-helix DNA-binding motif (Kaelin et al., 
1992; Cress et al., 1993).  
However, the crystal structure of E2F4-DP2 dimer by 
Zheng et al. rather reveals a structure related to the 
winged-helix DNA-binding motif. E2F4 and its DP 
partner bind to the E2F-consensus DNA sequence 
TTTC/GC/GCGC/G (Nevins, 1992; Slansky et al., 
1993) by means of a conserved Arg-Arg-Xxx-Tyr-Asp 
sequence (Zheng et al., 1999). Binding specificity of 
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E2F transcription factors to different target gene 
promoters is affected by the DNA sequence itself, E2F 
transcription factors, DP partners as well as other 
factors (Karlseder et al., 1996; Lin et al., 1996; Shin et 
al., 1996; Wells et al., 1997; Le Cam et al., 1999; Chen 
et al., 2002; Schlisio et al., 2002; Araki et al., 2003; 
Giangrande et al., 2003; Giangrande et al., 2004; Zhu et 
al., 2004). 
The transactivation domain of E2F transcription 
factors, including E2F4, mediates target gene 
transcription through two distinct mechanisms: 1- by 
recruiting general transcription machinery such as 
TBP/TFIID, TFIIA and TFIIH which promote RNA pol 
II pre-initiation complex (PIC) assembly (Hagemeier et 
al., 1993; Emili and Ingles, 1995; Pearson and 
Greenblatt, 1997; Ross et al., 1999; Vandel and 
Kouzarides., 1999) and 2- by relaxing chromatin 
structure at promoters by interacting with histone 
acetyltransferases (HAT) such as Tip60 (Taubert et al., 
2004), p300/CBP (Trouche and Kouzarides, 1996; 
Trouche et al., 1996; Martinez-Balbas et al., 2000; 
Marzio et al., 2000) and PCAF/GCN5 (Martinez-
Balbas et al., 2000; Marzio et al., 2000; Lang et al., 
2001). The transactivation domain also includes a 
pocket protein interacting domain. E2F4 interacts 
primarily with p130/RBL2, p107/RBL1 and to a lesser 
extent with Rb/RB1 (Beijersbergen et al., 1994; 
Ginsberg et al., 1994; Ikeda et al., 1996; Moberg et al., 
1996; Li et al., 1997). Pocket proteins modulate E2F 
transcription  
factor activity via two different mechanisms: 1- by 
preventing general transcription machinery and 
chromatin-remodeling protein recruitment (Helin et al.,
1992; Flemington et al., 1993; Hagemeier et al., 1993; 
Helin et al., 1993a; Pearson and Greenblatt., 1997) and 
2- by actively repressing gene transcription (Harbou  
and Dean, 2000; Singh et al., 2010). In fact, pocket 
proteins have been shown to recruit histone deacetyl s  
enzymes (HDACs) (Brehm et al., 1998; Luo et al., 
1998; Dahiya et al., 2000), the histone 
methyltransferase SUV39H1 (Nielsen et al., 2001; 
Vandel et al., 2001), SWI/SNF family members 
(BRG1, Brm) (Dunaief et al., 1994; Singh et al., 1995; 
Strobeck et al., 2000; Zhang et al., 2000; Iakova et l., 
2003), the Sin3B repressor complex (via RBP1 and 
SAP30) (David et al., 2008; Grandinetti and David., 
2008) and the ErbB3 binding protein Ebp1 (Zhang et 
al., 2003), all of which contribute to chromatin 
compaction and thus, to transcriptional repression 
(Kouzarides, 2007). 
During quiescence, E2F transcription factors are 
sequestered by hypophosphorylated forms of pocket 
proteins (pRb, p130 and p107) which prevent the 
activation of their target genes. Upon G1 progression, 
cyclin-dependent kinases (cdk)-cyclin complexes are 
activated and phosphorylate pocket proteins leading to 
the release of E2F transcription factors. Indeed, 
activation of cdk4 and cdk6, in association with cyclin 
D, leads to partial inactivation of Rb-like proteins. 
Further phosphorylation by cyclin E/cdk2 complex is 
required for total pocket protein inactivation and full 
release of E2F transcription factors.  
 
 
Adapted from Sardet et al., 1995; Magae et al., 1996; Zheng et al., 1999; Scime et al., 2008. 
DNA BD: Originally viewed as a basic helix-loop-helix DNA-binding motif (Kaelin et al., 1992; Cress et al., 1993), however the crystal 
structure of E2F-4/DP2 dimer binding to DNA revealed a winged-helix DNA-binding motif (Zheng et al., 1999). 
Dimerization Domain: Dimerization with DP proteins is required for proper E2F DNA binding and transactivation capacity. The Leuzine 
Zipper (100-128) and the Marked Box both contribute to DP dimerization (Kaelin et al., 1992; Chen et al., 2009). E2F transcription 
factors can bind DNA as homodimers although to a much lesser extent than heterodimers (Huber et al., 1993). 
Transactivation Domain: The transactivation domain mediates interaction with transcriptional machinery, co-activators and chromatin-
remodeling proteins (Emili and Ingles, 1995; Trouche and Kouzarides, 1996; Pearson and Greenblatt, 1997; McMahon et al., 1998; Ross 
et al., 1999; Vandel and Kouzarides, 1999; Martinez-Balbas et al., 2000; Marzio et al., 2000; Lang et al., 2001; Louie et al., 2004; Taubert 
et al., 2004) and includes the Pocket Protein Binding Domain. E2F4 interacts with p130/RBL2, p107/RBL1 and to a lesser extent with 
pRb/RB1 (Beijersbergen et al., 1994; Ginsberg et al., 1994; Ikeda et al., 1996; Moberg et al., 1996; Li et al., 1997). Association of E2F4 
with Rb protein family members (particularly p130/RBL2) prevents activation of E2F target genes and triggers their repression by 
recruiting transcriptional repression machinery (Zhang and Dean, 2001; Frolov and Dyson, 2004; Litovchick et al., 2007). E2F4 is the only 
E2F possessing a stretch of 13 consecutive serine residues in its transactivation domain (Sardet et al., 1995). 
 Numerous publications infer that E2F4 is a phosphorylated protein (Beijersbergen et al., 1994; Ginsberg et al., 1994; Vairo et al., 1995; 
Gaubatz et al., 2001; Popov et al., 2005; Scime et al., 2008) although only a few have identified specific phosphorylation sites: T14 and 
S16 are phosphorylated residues (Van Hoof et al., 2009); S281 and S285 are phosphorylated by IKKα and IKKβ and enhance E2F4 
nuclear localization and DNA-binding of the E2F4/p130 complex in human primary fibroblasts (Araki et al., 2008); S384 is phosphorylated 
in the DREAM or MMB complexes (Litovchick et al., 2011). 
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Thereafter, genes required for DNA synthesis and cell 
cycle progression are induced, allowing cells to enter 
S-phase and pursue their cell cycle (Cobrinik, 2005; 
Malumbres and Barbacid, 2009). 
In addition to pocket protein-mediated regulation, E2F4 
is also controlled by other mechanisms such as 
phosphorylation, antisenses (Yochum et al., 2007), 
reactive oxygen species (Kim and Lee, 2010), cofactrs 
and mainly by its subcellular localization. Indeed, E2F4 
protein levels are not significantly modulated during 
cell cycle progression; however, its nuclear localization 
is tightly regulated (Lindeman et al., 1997; Verona et 
al., 1997; Deschenes et al., 2004) (see below). 
Furthermore, many studies have reported E2F4 
phosphorylation but only a few have associated these 
phosphorylation events with a specific function 
(Beijersbergen et al., 1994; Ginsberg et al., 1994; Vairo 
et al., 1995; Gaubatz et al., 2001; Popov et al., 2005; 
Araki et al., 2008; Scime et al., 2008; Van Hoof et al., 
2009; Litovchick et al., 2011). For example, Araki et 
al., 2008 showed that E2F4 phosphorylation by IKKα 
and/or IKKβ leads to increased binding of the 
E2F4/p130 complex to DNA in TIG-3 human primary 
fibroblasts. 
Finally, Balciunaite et al., 2005 suggested that in early 
G1, both p107 and p130 are absent of certain repressed 
E2F4 target promoters, suggesting that another 
repression mechanism must be implicated. Moreover, 
Rayman et al., 2002 reported that pocket proteins are 
not required for mSin3B recruitment to certain E2F-
regulated promoters reinforcing the notion of a pocket 
protein-independent repression mechanism. Indeed, 
E2F4 can also recruit Host cell factor-1 (HCF-1), an 
important cell cycle regulator, which brings 
Sin3/HDAC complexes to E2F target gene promoters, 
repressing their transcription independently of pocket 
proteins (Tyagi et al., 2007). 
Expression 
In adult mouse tissues, Rempel et al. proposed that 
E2F4 is particularly abundant in hematopoietic tissues 
(i.e. thymus, spleen and bone marrow) and in the gut, in 
comparison to the heart, kidney, liver, brain and muscle 
(Rempel et al., 2000). However, other publications 
reported an ubiquitous expression of E2F4 (Gill and 
Hamel, 2000; D'Souza et al., 2001). Furthermore, it 
was suggested that E2F4 accounts for the vast majority 
of E2F cellular activity (Moberg et al., 1996; Puri et al., 
1997). Of note, E2F4 expression changes according to 
cellular status. During external epithelium formation, 
E2F4 transcripts are detectable in 11,5-day post coitum 
(dpc) embryos in all cells of the ectoderm. In 13,5-dpc 
embryos, the proliferating undifferentiated epithelial 
cells show strong E2F4 expression. At 18,5-dpc, 
proliferating basal cell layers of the primitive epidermis 
express abundant E2F4 transcripts whereas the 
suprabasal cell layers display negligible E2F4 signals 
(Dagnino et al., 1997b). During intestinal 
morphogenesis, E2F4 expression is high in the 
intervillus epithelium and almost absent in the non 
proliferating villus tips and in the underlying 
mesenchyme (Dagnino et al., 1997b). E2F4 transcript 
are widespread in the central and peripheral developing 
nervous systems. In the developing brain, E2F4 is 
ubiquitously expressed with the highest levels detect d 
in ventricular and subventricular zones (Dagnino et al., 
1997a; Ruzhynsky et al., 2007). 
Localisation 
E2F4 exhibits a CRM1-dependent bipartite nuclear 
export signal (NES) which mediates its export to the
cytoplasm. The two elements of E2F4 NES are referred 
to as NES1 (residues 61 to 70) and NES2 (residues 91 
to 100) (Gaubatz et al., 2001). Therefore, E2F4 relies 
on other proteins to reach the nucleus, such as DP2 
(Magae et al., 1996; Verona et al., 1997; Puri et al., 
1998) or pocket proteins (Verona et al., 1997; Gaubatz 
et al., 2001; Apostolova et al., 2002; Rayman et al., 
2002). Studies have shown that nuclear E2F4, triggeed 
by the addition of an ectopic NLS or co-expression 
with DP2, is transcriptionally active and can induce 
DNA synthesis (Lindeman et al., 1997; Muller et al., 
1997; Verona et al., 1997; Puri et al., 1998; Gill and 
Hamel, 2000). Of note, Apostolova et al. suggested that 
E2F4 may also travel to the nucleus on its own 
(Apostolova et al., 2002). 
A number of studies have highlighted the importance of 
regulating the subcellular localization of E2F4 (Magae 
et al., 1996; Lindeman et al., 1997; Muller et al.,1997; 
Verona et al., 1997; Puri et al., 1997; Puri et al., 1998; 
Gill and Hamel, 2000; Deschenes et al., 2004). In 
immortalized fibroblasts and certain cancer cells, E2F4 
is expressed in the nucleus of quiescent cells and as 
cells progress through G1 and enter the S phase, E2F4
translocates to the cytoplasm (Lindeman et al., 1997; 
Muller et al., 1997; Verona et al., 1997). In addition, 
overexpression of E2F4 in certain asynchronously 
growing cancer cells or fibroblasts revealed that E2F4 
is primarily expressed in the cytoplasm (Magae et al., 
1996; Lindeman et al., 1997; Muller et al., 1997; 
Verona et al., 1997). By contrast, endogenous E2F4 is 
found in the nucleus of proliferating basal epidermal 
cells (Paramio et al., 2000), proliferating intestinal 
crypt cells (Deschenes et al., 2004) and proliferating 
cardiomyocytes (van Amerongen et al., 2009). 
Likewise, overexpression of E2F4 in mice epidermis 
under the K5 promoter leads to E2F4 expression in the 
nucleus of cycling keratinocytes in the basal cell layer 
and the hair follicle resulting in hyperplasia and 
increased tumor formation in a mouse skin model of 
multistage carcinogenesis (Wang et al., 2000). 
Moreover, endogenous E2F4 is observed in the nucleus 
of many differentiated cells including ciliated epithelial 
cells (Danielian et al., 2007), myotubes (Puri et al.,
1997; Puri et al., 1998) and neurons (Persengiev et al., 
1999). Overall, these results suggest that E2F4 can a t 
as either an activator or an inhibitor of transcription, 
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proliferation and differentiation. Therefore, E2F4 
localization control must be tightly regulated in a 
timely and restricted manner. 
Function 
The main characterized function of E2F transcription 
factors is the regulation of the cell cycle. E2F factors 
induce a number of genes required for DNA synthesis, 
including dihydrofolate reductase, thymidine kinase, 
DNA polymerase α, and for cell cycle progression, 
including cyclin A, cyclin E, c-myc, E2F and cdc2, to 
name a few (Stevens and La Thangue, 2003; Tsantoulis 
and Gorgoulis, 2005). In quiescent fibroblasts and 
certain cancer cells, E2F4 (mainly in complex with 
p130) binds to DNA and contributes to active 
repression of E2F target genes preventing cell cycle 
progression (DeGregori, 2002; Trimarchi and Lees, 
2002; Cam et al., 2004). Upon G1 phase progression, 
E2F4 translocates to the cytoplasm while E2F1-3a 
transactivates genes required for S phase entry 
(Takahashi et al., 2000; Rayman et al., 2002; Trimarchi 
and Lees, 2002). However, no detectable defect either 
in cell cycle regulation or target gene expression was 
identified in E2F4-/- mouse embryonic cells, suggesting 
its compensation by other E2F members (Humbert et 
al., 2000; Rempel et al., 2000; Landsberg et al., 2003). 
Accordingly, dual loss of E2F4 and E2F5 impairs 
pocket protein-mediated cell cycle exit (Gaubatz et al., 
2000). 
Interestingly, loss of p107 and p130 triggers a massive 
E2F4 relocalization to the cytoplasm accompanied by a 
hyperacetylation of nucleosomes proximal to E2F 
binding sites, producing an important de-repression of 
E2F target genes (Rayman et al., 2002). Indeed, during 
quiescence, E2F4/p130 or E2F4/p107 complexes are 
associated with E2F-responsive genes and repress thir 
transcription (Takahashi et al., 2000; Wells et al., 2000; 
Rayman et al., 2002). Recent data also implicate E2F4 
as part of a multiprotein complex referred to as the
DREAM complex (DP, RB-like, E2F4 and MuvB). In 
fact, the DREAM complex binds to the promoters of 
more than 800 cell cycle-regulated genes during 
quiescence and favors their repression (Litovchick et 
al., 2007; Schmit et al., 2007). This E2F4 repressing 
effect is also observed during cell cycle arrest 
associated with aging and differentiation.  
For example, in aging mice, reduced proliferation of 
hepatocytes is accompanied by the association of 
Brm1/C/EBPα/E2F4/Rb repressive complex to E2F 
target genes (Iakova et al., 2003). In keratinocytes, 
E2F4 in complex with p130 recruits HDAC1 and 
represses Cdc25A, correlating with cell cycle arrest 
(Iavarone and Massague, 1999). 
In keeping with the above concept, (Grandinetti and 
David, 2008) proposed the following model. Upon 
entry into quiescence, repression of E2F responsive 
genes responsible for cell cycle progression is initiated 
by the recruitment of E2F4/5 bound to a Rb-like 
protein (pRb, p130, p107) to target promoters. Sin3B 
recruitment to the pocket protein is then brought by 
Retinoblastoma Binding protein 1 (RBP1) and Sin3 
Associated Protein 30 (SAP30) adaptor proteins. 
Thereafter, Sin3B recruits HDACs, which desacetylate 
histones, and RBP2, a histone demethylase responsible 
for demethylation of histones on lysine 4. All of these 
events promote nucleosome assembly rendering 
chromatin less permissive to transcription. Upon 
permanent cell cycle withdrawal (terminal 
differentiation or senescence), further recruitment of 
SUV39H1 enables methylation of histones on lysine 9 
creating docking sites for HP1 protein and thus driving 
heterochromatinization and stable repression of E2F 
target genes (Narita et al., 2003; Grandinetti and David, 
2008). 
Although E2F4 has been particularly described as a 
repressor of both transcription and cell cycle 
progression (Vairo et al., 1995; Muller et al., 1997; 
Rayman et al., 2002), several studies have reported 
other roles such as 1- its binding to E2F-responsive 
elements as a pocket protein-free E2F during S phase, 
2- its capacity to induce E2F target genes and 3- its 
implication in proliferation. Hence, these studies 
suggest that E2F4 can also act as a transcriptional 
activator (Verona et al., 1997; Wells et al., 1997; Ross 
et al., 1999; Lang et al., 2001; Garneau et al., 2009; van 
Amerongen et al., 2009). For example, studies carried 
out by Lo et al., 2011 demonstrated that the majority f 
E2F4 binding sites are located proximal to transcription 
start sites. There, E2F4 has been shown to stabilize 
TFIID/TFIIA complex thereby preventing Rb repressor 
effect and promoting PIC assembly (Ross et al., 1999). 
E2F4 can recruit the potent acetyltransferase GCN5 
and the cofactor TRRAP which promote E2F4 
transcriptional activity (Lang et al., 2001).  
Host cell factor-1 also interacts with E2F4 and plays 
both co-activator (Knez et al., 2006) or co-repressor 
(Tyagi et al., 2007) roles in the regulation of E2F4-
controlled promoters. Accordingly, forced expression 
of nuclear E2F4 promotes S-phase entry into 
cardiomyocytes (Ebelt et al., 2005; van Amerongen et 
al., 2009).  
Moreover, nuclear E2F4 expression is associated with
proliferation of rapid renewing tissues such as bone 
marrow (Kinross et al., 2006; Zhang et al., 2010), 
digestive tract (Rempel et al., 2000; Garneau et al., 
2009) and skin (Wang et al., 2000; Wang et al., 2001). 
Many in vivo and in vitro studies have led to the 
identification of numerous roles of E2F4 in different 
cellular processes such as nervous system development, 
intestinal homeostasis, bone development, myogenesis, 
adipogenesis and erythropoiesis, to name a few. E2F4 
gene deletion in mice leads to important neonatal 
lethality due to chronic rhinitis and increased 
susceptibility to opportunistic infections (Humbert et 
al., 2000). Many factors contribute to the observed 
neonatal lethality in these mice. First, ciliated cells are 
absent from the entire airway epithelium and are 
replaced by mucin-secreting cells, creating a mucus 
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overflow in the nasal cavities allowing microbial 
colonization (Danielian et al., 2007). Secondly, sonic  
hedgehog (Shh) signaling is dysregulated which 
impairs eye patterning, self-renewal capacity of neural 
progenitor cells and ventral telencephalic structure 
formation during brain development (Ruzhynsky et al., 
2007; Ruzhynsky et al., 2009; Swiss and Casaccia, 
2010). Studies also highlighted E2F4 requirement for 
proper bone development, especially for calvarial 
ossification (Humbert et al., 2000; Miller et al., 2010). 
These generated craniofacial defects are thought to 
contribute to the aberrant accumulation of 
proteinaceous secretions in nasal cavities leading to 
lethality (Humbert et al., 2000). Thirdly, recall 
proliferation of CD8+ T-lymphocytes, which 
participate in viral infections control, is impaired 
(Bancos et al., 2009). 
Aside from its role during brain development, 
implication of E2F4 in neuronal differentiation has 
been strengthened by in vitro studies using the 
pheochromocytoma line (PC-12 cells), which show 
reduced neuronal differentiation following E2F4 
depletion and accelerated NGF-induced neuronal 
maturation with E2F4 overexpression (Persengiev et 
al., 1999). Other laboratories have also documented a 
role for E2F4 in repressing adipocyte differentiation 
independently of its cell cycle regulation propertis but 
through PPARγ repression, a primordial factor in 
adipogenesis (Fajas et al., 2002; Landsberg et al., 2003; 
Tseng et al., 2005). 
E2F4 also appears to play a critical role in rapid 
renewing tissues. In the gut, E2F4 is highly and 
preferentially expressed in the nucleus of proliferative 
cells (Dagnino et al., 1997b; Deschenes et al., 2004; 
Garneau et al., 2009). Loss of E2F4 in the small 
intestine results in a significant decline in proliferative 
zones (crypts) and a shortening and a reduction in the 
number of intestinal villi (Rempel et al., 2000). The 
role of E2F4 in maintaining intestinal homeostasis i  
also reinforced by the fact that it is overexpressed in the 
nucleus of colorectal cancer cells, contributing to 
hyperproliferation (Mady et al., 2002; Garneau et al., 
2007; Garneau et al., 2009). In human and mouse 
epidermis, E2F4 is expressed in the basal and the 
immediately suprabasal cells, fading in upper cell 
layers (Dagnino et al., 1997b; Paramio et al., 2000; 
Wang et al., 2000; D'Souza et al., 2001). Although 
E2F4 has been reported to contribute to cell cycle arr st 
and differentiation in keratinocytes (Iavarone and 
Massague., 1999; Paramio et al., 2000), overexpressed 
E2F4 increases keratinocyte proliferation leading to 
hyperplasia and to an increased response to a two-step 
skin carcinogenesis assay (Wang et al., 2000; Wang et 
al., 2001). Finally, E2F4-deficient mice display a 
marked macrocytic anemia caused by impaired cell 
cycle progression and proliferation of fetal erythroid 
precursors also accompanied by maturation defects in 
multiple other hematopoietic lineages (Rempel et al., 
2000; Kinross et al., 2006; Zhang et al., 2010). 
In addition to the roles identified in proliferation, 
differentiation and development, other unconventional 
functions have been attributed to E2F4. Indeed, E2F4 
binds various genes having functions in mitochondrial 
biogenesis, metabolism, cytoskeleton and mRNA 
processing (Cam et al., 2004). Moreover, E2F4 is 
thought to regulate the expression of certain miRNAs 
(Lee et al., 2011), control DNA repair (Ren et al.,2002; 
DuPree et al., 2004; Bindra and Glazer, 2007; Crosby 
et al., 2007; Dominguez-Brauer et al., 2009; Hegan et 
al., 2010; Lee et al., 2011), control survival in certain 
specific cell contexts (Chang et al., 2000; Wang et al., 
2000; Ebelt et al., 2005; Garneau et al., 2007; Yang et 
al., 2008; Lee et al., 2011) as well as regulate aging and 
senescence (Iakova et al., 2003; Litovchick et al., 2011; 
Martin et al., 2011). Lastly, although the majority of 
E2F4 binding sites are located near transcription start 
sites and contribute to direct activation or repression of 
transcription (Lee et al., 2011; Lo et al., 2011), many 
sites are frequently localized more than 20 kb away 
from any annotated transcription start sites, suggesting 
that E2F4 can also act as a long-range transcriptional 
regulator (Lee et al., 2011). 
Homology 
E2F4 is more related to E2F5 (69% identity, 80% 
similarity) than E2F1-3 (between 36% and 40% 
identity, between 52% and 60% similarity) (Sardet et 
al., 1995). In the E2F4 DNA-binding domain, residues 
mediating contact with DNA are conserved throughout 
the E2F transcription factor family (Zheng et al., 1999).  
Seventy-five percent of the DP interaction interface is 
identical within E2F transcription factors family 
(Zheng et al., 1999) and the pocket protein interaction 
domain of E2F4 has 48% homology with the Rb-





Summary: Mutation (AGC repeat) (Yoshitaka et al., 
1996; Souza et al., 1997; Ikeda et al., 1998; Moriyama 
et al., 2002); Increased expression (Mady et al., 2002; 
Garneau et al., 2009). 
Many studies have reported the presence of mutations 
in E2F4 AGC trinucleotide repeats in colorectal cancer 
bearing microsatellite instability (MSI). The more 
frequent mutations observed are the deletion or the 
addition of a trinucleotide AGC and the deletion of 7 
trinucleotides (Yoshitaka et al., 1996; Souza et al.,
1997; Ikeda et al., 1998; Moriyama et al., 2002). 
Furthermore, Takashima et al., 2001, studied the 
impact of E2F4 mutations and observed an increase in 
nuclear expression, in transcriptional activity as well as 
in proliferation rate of fibroblasts overexpressing these 
mutants. 
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Gastric carcinoma 
Note 
Summary: Mutation (AGC repeat) (Kim et al., 1999; 
Ogata et al., 2001). 
Kim et al., 1999, analyzed 56 gastric adenomas and 167 
gastric carcinomas and found that frameshift mutations 




Summary: Amplification of chromosome arm 16q (Yu 
et al., 2001).  
Comparative genomic hybridization (CGH) analysis 
revealed amplifications of chromosome arm 16q in 
6/12 human transitional cell carcinoma (TCC) lines 
(more frequent in low-grade tumors) (Yu et al., 2001). 
Hepatocellular carcinoma (HCC) 
Note 
Summary: LOH on chromosome 16 (Sakai et al., 
1992). 
Using restriction fragment length polymorphism 
(RFLP) analysis on sixty-eight HCC specimens and 
their corresponding non-tumor liver tissues, a loss f 
heterozygosity was frequently observed on 
chromosome 16: specifically the MT2 locus at 16q21-
22.1 (15%) and the HP locus at 16q22.1-22.2 (39%) 
(Sakai et al., 1992). 
Breast cancer 
Note 
Summary: Deletion of chromosome arm 16q22 or 
LOH (Dorion-Bonnet et al., 1995; Iida et al., 1997; 
Cleton-Jansen et al., 2001); Decreased expression (H  
et al., 2001); Increased nuclear expression (Rakha et 
al., 2004; Rakha et al., 2005). 
Loss of chromosomal material at 16q22.1 is one of the 
most frequent genetic aberrations found in breast 
carcinogenesis suggesting the presence of a tumor 
suppressor gene (TSG) at this region (Dorion-Bonnet et 
al., 1995; Iida et al., 1997; Cleton-Jansen et al., 2001).  
E2F4 is one of the candidate genes localized in this 
region and therefore was analyzed in different studies. 
Ho et al., 2001, studied E2F4 protein expression in 10 
primary breast carcinomas and 10 metastatic nodal 
tissues. The authors found a lower E2F4 protein 
expression in 7/10 primary breast carcinomas and in all 
(10/10) metastatic nodal tissues when compared to 
corresponding normal breast tissues. No tumor-specific 
mutation was detected, but polymorphisms were 
identified in the polyserine tract of E2F4 (3/11). Ho et 
al., 2001, further suggested that E2F4 is likely to 
function as a tumor suppressor in breast cancer. 
Another group published two complementary and more 
in-depth studies arguing against the role of E2F4 as a 
TSG in breast cancer. Indeed, Rakha et al., 2005, used
a Multiplex Amplifiable Probe Hybridization (MAPH) 
method to measure DNA copy-number at chromosome 
arm 16q22.1 in forty-nine invasive lobular, low-grade 
invasive ductal or tubular breast carcinoma samples. 
No correlation was detected between the expression of 
E2F4 with its gene's copy number.  
Likewise, no significant loss or decrease in E2F4 
protein levels was observed in malignant tissues. 
However, the authors did describe a correlation 
between increased nuclear expression of E2F4 and 
tumors with higher histological grade and positive 
lymph node disease whereas E2F4 was expressed in 
both the nuclei and cytoplasm in normal mammary 
epithelial cells, thus suggesting an oncogenic rather 
than a tumor suppressor role for this factor in breast 
cancer.  
The same group (Rakha et al., 2004) also analyzed 265 
breast carcinomas for E2F4 protein expression and 
found a correlation between increased nuclear 
expression of E2F4 and indicators of poor prognosis 
including larger tumor size, grade 3 lesions, lymph 
node stage and poorer Nottingham prognostic index 
group.  
Increased E2F4 expression was also seen in association 
with the development of recurrent disease, distant 
metastasis and poorer outcome including poorer overall 
survival time and shorter disease-free interval. 
Prostate cancer 
Note 
Summary: Increased expression (Waghray et al., 
2001). 
Using serial analysis of gene expression (SAGE), 
Waghray et al., 2001, found that E2F4 was 
overexpressed by more than five-fold in prostate tumor 
tissues compared to the normal surrounding tissues.  
Immunohistochemistry analysis further revealed strong 
E2F4 staining in epithelial cells of tumor  
 
 




Summary: Mutation (AGC repeat) (Komatsu et al., 
2000). 
Komatsu et al., 2000, analyzed nine childhood acute 
lymphoblastic leukemia (ALL) samples, five acute 
myelocytic leukemia (AML) samples and ten adult T-
cell leukemia (ATL) samples: frameshift mutations 
were found in E2F4 trinucleotide AGC repeats in 20% 
of ATL samples (3 AGC codon insertions) and in 11% 
of childhood ALL samples (6 AGC codon deletions). 
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